Imugene (IUGNF)
OTHER OTC:IUGNF
IUGNF Stock Chart & Stats
$0.18
>-$0.01(-3.57%)
At close: 4:00 PM EST
$0.18
>-$0.01(-3.57%)
Day’s Range― - ―
52-Week Range$0.06 - $0.65
Previous CloseN/A
Volume3.00K
Average Volume (3M)16.95K
Market Cap
$28.72M
Enterprise Value$38.71M
Total Cash (Recent Filing)$14.14M
Total Debt (Recent Filing)$5.02M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Sep 02, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding415,835,050
10 Day Avg. Volume11,247
30 Day Avg. Volume16,948
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.15
Price to Sales (P/S)21.99
P/FCF Ratio-1.07
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue12.33
Enterprise Value/Gross Profit13.88
Enterprise Value/Ebitda-0.66
Forecast
1Y Price Target
$0.18Price Target Upside-1.10% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.1
Revenue Forecast (FY)$3.62M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetImugene's low debt-to-equity (0.24) and moderate equity ratio reduce interest burden and refinancing pressure, giving management financial flexibility during lengthy clinical programs. Lower leverage supports surviving development timelines and negotiating partnerships without heavy covenant constraints.
Diverse Development PipelineA multi-modal immuno-oncology pipeline spreads scientific and commercial risk across engineered oncolytic viruses, B-cell activating therapies and CAR-T related approaches. Multiple modality assets create several independent value inflection points, improving chances for partner interest or staged commercialization.
Access To Non-dilutive Funding PathwaysThe company's industry position and clinical-stage assets create realistic opportunities for collaborations, licensing deals or grant funding. Such non-dilutive routes, if secured after clinical readouts, can finance development, preserve equity and validate programs for longer-term sustainability.
Bears Say
Severe Revenue Decline And LossesA dramatic revenue contraction and persistent negative margins materially weaken internal funding capacity and indicate program delays, discontinued contracts or restructuring. Ongoing losses erode equity, forcing dependence on external financing to sustain R&D and trial progress over the medium term.
Negative Operating Cash Flow / Cash Generation IssuesConsistently negative operating cash flow signals that core activities consume cash rather than generate it, increasing reliance on financing. Even with some positive free cash flow metrics, persistent operational cash burn constrains runway and reduces ability to self-fund trials or respond to unexpected costs.
No Recurring Product Revenue; Funding RelianceAs a development-stage biotech without commercial products, Imugene depends on equity raises, partnerships or grants. This funding model creates execution risk: adverse market conditions or weak clinical results can impair access to capital, delaying programs and diluting shareholders over time.
Imugene News
IUGNF FAQ
What was Imugene’s price range in the past 12 months?
Imugene lowest stock price was $0.06 and its highest was $0.65 in the past 12 months.
What is Imugene’s market cap?
Imugene’s market cap is $28.72M.
When is Imugene’s upcoming earnings report date?
Imugene’s upcoming earnings report date is Sep 02, 2026 which is in 88 days.
How were Imugene’s earnings last quarter?
Imugene released its earnings results on Feb 25, 2026. The company reported -$0.093 earnings per share for the quarter, beating the consensus estimate of -$0.243 by $0.15.
Is Imugene overvalued?
According to Wall Street analysts Imugene’s price is currently Overvalued.
Does Imugene pay dividends?
Imugene does not currently pay dividends.
What is Imugene’s EPS estimate?
Imugene’s EPS estimate is -0.03.
How many shares outstanding does Imugene have?
Imugene has 415,835,050 shares outstanding.
What happened to Imugene’s price movement after its last earnings report?
Imugene reported an EPS of -$0.093 in its last earnings report, beating expectations of -$0.243. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Imugene?
Currently, no hedge funds are holding shares in IUGNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imugene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.18 (-1.10% Downside)
$0.18 (-1.10% Downside)
Blogger Sentiment
Bullish
IUGNF Sentiment 60%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $64.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.97%
12-Months-Change
Fundamentals
Return on Equity
-134.65%
Trailing 12-Months
Asset Growth
-39.73%
Trailing 12-Months
Company Description
Imugene
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
IUGNF Stock 12 Month Forecast
Average Price Target
$0.18
▼(-1.10% Downside)
Technical Analysis
Immutep Ltd
―
Prescient Therapeutics Limited
―
Telix Pharmaceuticals
―
Noxopharm Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Ownership Overview
3.95% Insiders
0.88% Mutual Funds
― Other Institutional Investors
95.16% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---